Article · 30 Jul 2026
Case reportPublished 30 Nov 2010
Treatment of androgen-refractory prostate cancer with UV light blood-irradiation: A case report.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
UV blood-irradiation (UBI) using the ImmunoModulator (IM) is in clinical studies for treatment of patients infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Preclinical studies suggest UBI could be also effective against cancer. To further explore this potential, a patient with an aggressive prostate cancer that has recently become androgen-refractory was treated with UBI using the IM. Cancer progression was monitored by means of prostate specific antigen (PSA). Prior to treatment with UBI PSA level increased exponentially over 6 months with a doubling time of 2.3 months. After treatment PSA level increased at a slower rate of 4.0 months doubling time. It is concluded that UBI treatment using the IM has an inhibitory effect on the growth of prostate cancer, presumably by stimulating a cellular immune response. Since androgen-refractory prostate cancer is invariably fatal, clinical studies with the IM are warranted for this indication.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Medicine and Medical Sciences.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Medicine and Medical Sciences
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Ehud Ben-Hur”
- BylineArticles whose byline prints “Stuart Weg”
- BylineArticles whose byline prints “Thomas R. Petrie”
